APLT NASDAQ
New York City, NY 10017
US
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Kanter Stacy J. | D-Return | 22,500 | $0.09 | 2026-02-03 |
| Kanter Stacy J. | D-Return | 200,000 | $0.40 | 2026-02-03 |
| Kanter Stacy J. | U-Tender | 42,500 | $0.09 | 2026-02-03 |
| Kanter Stacy J. | D-Return | 16,500 | $1.05 | 2026-02-03 |
| Hooks Corwin Dale | D-Return | 862,500 | $0.09 | 2026-02-03 |